GlassScriptPhysician profile
Paul D Charron
NPI 1700093515
$1,297.96
in general payments reported to CMS, 2019-2025
17 companies · $38.45 in 2025
The $38.45 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $329 · 2021: $411 · 2022: $64.49 · 2023: $167 · 2024: $41.45 · 2025: $38.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $338.66 | 2020-2023 | Echelon Flex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.16 | 2019-2022 | |
| Intuitive Surgical, INC. | $149.92 | 2019-2021 | |
| Medtronic, INC. | $140.46 | 2021-2023 | Interstim |
| Braintree Laboratories, INC. | $135.02 | 2019-2023 | Suflave |
| Axonics, INC. | $78.61 | 2020-2023 | Axonics |
| Merck Sharp & Dohme LLC | $35.99 | 2019-2025 | Bridion |
| Pacira Pharmaceuticals Incorporated | $31.70 | 2019-2024 | Exparel |
| Mallinckrodt Hospital Products INC. | $20.87 | 2021 | |
| Sanara Medtech INC. | $20.11 | 2025 | Celleraterx |
| Boston Scientific Corporation | $19.28 | 2019 | |
| Baudax Bio INC. | $18.58 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.13 | 2023 | Gattex |
| Integra Lifesciences Corporation | $15.77 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Mimedx Group, INC. | $14.22 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $12.82 | 2020 | |
| Reprise Biomedical, INC. | $8.66 | 2024 | Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Charron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.